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Classification and rescue of ROMK mutations underlying hyp-
erprostaglandin E syndrome/antenatal Bartter syndrome.
Background. Mutations in the renal K channel ROMK
(Kir 1.1) cause hyperprostaglandin E syndrome/antenatal Bart-
ter syndrome (HPS/aBS), a severe tubular disorder leading to
renal salt and water wasting. Several studies confirmed the
predominance of alterations of current properties in ROMK
mutants. However, in most of these studies, analysis was re-
stricted to nonmammalian cells and electrophysiologic meth-
ods. Therefore, for the majority of ROMK mutations, distur-
bances in protein trafficking remained unclear. The aim of the
present study was the evaluation of different pathogenic mecha-
nisms of 20 naturally occurring ROMK mutations with consecu-
tive classification into mutational classes and identification of
distinct rescue mechanisms according to the underlying defect.
Methods. Mutated ROMK potassium channels were expressed
in Xenopus oocytes and a human kidney cell line and analyzed
by two electrode voltage clamp analysis, immunofluorescence,
and Western blot analysis.
Results. We identified 14 out of 20 ROMK mutations that
did not reach the cell surface, indicating defective membrane
trafficking. High expression levels rescued six out of 14 ROMK
mutants, leading to significant K currents. In addition, two
early inframe stop mutations could be rescued by aminoglyco-
sides, resulting in full-length ROMK and correct trafficking to
the plasma membrane in a subset of transfected cells.
Conclusion. In contrast to previous reports, most of the in-
vestigated ROMK mutations displayed a trafficking defect that
might be rescued by pharmacologic agents acting as molecular
chaperones. The evaluation of different disease-causing mecha-
nisms will be essential for establishing new and more specific
therapeutic strategies for HPS/aBS patients.
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The inwardly rectifying renal outer medullary K
channel ROMK (Kir 1.1) plays a critical role in renal
salt reabsorption in the thick ascending limb of Henle’s
loop (TAL) [1, 2]. In the TAL, sodium chloride is reab-
sorbed in symport with K via the bumetanide-sensitive
Na-K-2Cl cotransporter NKCC2. As the luminal K
concentration is low, a permanent K recycling via ROMK
is essential for proper function of NKCC2 [3, 4]. Conse-
quently, mutations in both, SLC12A1, encoding NKCC2,
and in KCNJ1, encoding ROMK, lead to hyperprosta-
glandin E syndrome/antenatal Bartter syndrome (HPS/
aBS), a severe salt-losing tubular disorder with antenatal
onset [5–7]. The clinical presentation of HPS/aBS patients
is characterized by polyhydramnios leading to premature
delivery, severe salt and water losses postnatally, hypo-
kalemic alkalosis, hyperprostaglandinuria, and hypercal-
ciuria associated with medullary nephrocalcinosis [8, 9].
Numerous mutations distributed all over the protein
have been identified in patients with HPS/aBS, including
nonconservative amino acid exchanges, premature stop
mutations, and large deletions [5, 7, 10–14]. Until now,
most of the missense mutations have been clustered in
two regions (Fig. 1): (1) the channel core region (amino
acids 84 to 180) and (2) the pH sensor, which depends
on the cytosolic arginine/lysine/arginine (Arg/Lys/Arg)
triad assembled by amino acid residues at positions 41,
80, and 311.
Mutations in the channel core region are thought to
lead to defective K conductance due to conformational
changes [15], whereas mutations affecting the Arg/Lys/
Arg triad cause a shift of the pH gating off the neutral
range to more alkaline pH values [11]. However, many
ROMK mutations do not affect these two regions; there-
fore, alternative pathogenic mechanisms have to be con-
sidered.
As shown for mutations in the cystic fibrosis transmem-
brane regulator (CFTR), five basic pathogenic mechanisms
can be differentiated leading to a classification into five
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Fig. 1. Distribution of hyperprostaglandin E
syndrome/antenatal Bartter syndrome (HPS/
aBS) missense mutations in ROMK1. Mutations
investigated in this study are indicated by dark
gray circles. Most mutations cluster in the chan-
nel core region or in vicinity of the pH sensor
domain.
mutational classes [16]: (1) class I mutations encompass
premature stop-codons leading to a truncated mRNA
transcript, (2) class II mutations lead to defective pro-
cessing/trafficking, (3) class III mutations are character-
ized by disturbed regulation, (4) class IV encompasses
mutations with decreased Cl currents (e.g., due to con-
formational changes), and (5) class V mutations lead to
only small amounts of intact RNA due to splicing defects
or due to mutations affecting the promotor. The identifi-
cation and differentiation of these mechanisms is of spe-
cial interest in view of pharmacologic attempts to restore
protein function. Beside pharmacologic agents that act
as molecular chaperones such as butyrates or glycerol
for class II mutations [16, 17], aminoglycoside antibiotics
have been shown to be effective in treating premature
stop mutations (class I) in various genes, such as CFTR
or dystrophin [18, 19]. Aminoglycosides cause extensive
misreading of the RNA code by binding a specific site in
ribosomal RNA and disturbing codon-anticodon recogni-
tion at the aminoacyl-tRNA acceptor site [20, 21]. Depend-
ing on the aminoglycoside, the surrounding context, and
the stop mutation (UGA, UAA, or UAG), the synthesis
of the full-length protein reached up to 25% of normal
levels [18, 22]. A pilot study in cystic fibrosis patients
carrying a premature stop mutation lead to significant
repolarization of the nasal epithelium indicating chloride
transport after topical application of gentamicin [23].
The aim of this study was the evaluation of different
pathogenic mechanisms of 20 naturally occurring ROMK
mutations in heterologous expression systems with con-
secutive classification into five mutational classes as pre-
requisites for new therapeutic approaches that are aimed
at the restoration of protein function. The distribution
of the investigated mutations is shown in Figure 1.
Following site-directed mutagenesis, ROMK1 con-
structs were analyzed in Xenopus oocytes by electro-
physiologic methods and immunofluorescence. The re-
sults were subsequently confirmed in HEK293 cells.
According to the underlying defects, we assigned the
mutations investigated in our study and those ROMK
mutations that had already been functionally analyzed
before into five mutational classes and applied different
techniques for restoration of protein function.
METHODS
Mutational analysis
Mutational analysis was performed in patients diag-
nosed as HPS/aBS who presented with the characteristic
clinical triad of polyhydramnios, hyposthenuria/isosthen-
uria, and nephrocalcinosis. Genomic DNA was extracted
from whole blood using standard methods and subse-
quently screened for mobility shifts by single-strand con-
formation polymorphism analysis (SSCA) [13]. Ampli-
fied DNA fragments that yielded aberrant band patterns
were subsequently subjected to direct sequencing using
the ALF express (Pharmacia Biotech, Freiburg, Ger-
many). Mutations were confirmed by sequencing both
strands from patient and parents.
Synthesis of ROMK1 constructs
For expression in Xenopus oocytes, rat ROMK1
(rROMK1) cDNA cloned into the polyadenylated pBF
expression vector with a C-terminal flag epitope (a gift
of B. Fakler, University of Freiburg, Germany) was used.
Site-directed mutagenesis was performed using 23 to 25
oligomer nucleotide primers with the engineered nucleo-
tide exchange in the center of the primer pairs (Quik
Change; Stratagene, La Jolla, CA, USA). The entire
rROMK1 coding region was sequenced (ABI prism, Fos-
ter City, CA, USA).
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Complementary RNA was transcribed in vitro in the
presence of capping analog G (5) ppp (5) G using MluI
linearized cDNA templates (SP6 mMessage Machine
Kit; Ambion, Austin, TX, USA). After 15 minutes of
DNase I treatment, cRNA was precipitated and purified
by lithium chloride precipitation, as described by the
manufacturer. Yield and concentration were measured
spectrophotometrically (RNA/DNA calculator, Gene-
QuantII; Pharmacia Biotech, Freiburg, Germany) and
by agarose gel electrophoresis.
For expression in HEK293 cells, human ROMK1
(hROMK1) tagged with an N-terminal HA-epitope was
cloned in a pEGFP-C1 vector (Clontech, Palo Alto, CA,
USA) and site-directed mutagenesis was performed, as
described above. Again, mutants were verified by se-
quencing of the entire hROMK1 coding region.
Oocyte isolation and injection
Oocytes were obtained from female Xenopus laevis and
defolliculated by incubation for 1 hour in modified ORII
solution [82.5 mmol/L NaCl, 2 mmol/L KCl, 1 mmol/L
MgCl2 1, 5 mmol/L N-2-hydroxyethylpiperazine-N-2-ethane-
sulfonic acid (HEPES), pH 7.5] containing 2 mg/mL col-
lagenase A (Roche Molecular Biochemicals, Mannheim,
Germany). Stages V and VI oocytes were selected and
stored at 16C in ND96 solution (96 mmol/L NaCl 96, 2
mmol/L KCl, 1.8 mmol/L CaCl2, 1 mmol/L MgCl2, 5
mmol/L HEPES, pH 7.5) supplemented with 20 g/mL
gentamicin, 0.5 mmol/L theophylline, and 2.5 mmol/L
sodium pyruvate. Defolliculated oocytes were injected
with 50 nL water containing 0.1 ng and 1 ng cRNA and
incubated 2 to 3 days at 16C.
Immunostaining of mutant ROMK in Xenopus oocytes
After removal of the vitellin membranes, oocytes were
fixed in Dent’s fixative [20% methanol in dimethyl sulfox-
ide (DMSO)] at20C overnight. Oocytes were then incu-
bated for 3 hours at room temperature or at 4C overnight
with the M2 anti-Flag antibody (Sigma Chemical Co., St.
Louis, MO, USA) and washed with phosphate-buffered
saline (PBS) for 2 to 3 hours. Subsequently, all oocytes
were incubated with a Cy3-conjugated secondary anti-
body (Dianova, Hamburg, Germany). Stained oocytes
were fixed with 3.7% paraformaldehyde, embedded with
Technovit 7100 (Heraeus Kulzer, Wehrheim, Germany)
and cut to 4 m sections. Analysis was performed with
a fluorescence microscope (Leica DMRB, Wetzlar, Ger-
many) and with the Leica QWin software.
Electrophysiology
Two to three days after injection, two-electrode volt-
age clamp measurements were performed at room tem-
perature with a GeneClamp 500 amplifier (Axon Instru-
ments, Union City, CA, USA). Currents were recorded
in KD96 solution (89 mmol/L KCl, 1.8 mmol/L CaCl2,
1 mmol/L MgCl2, 5 mmol/L HEPES, pH 7.4) during volt-
age ramps from –20 mV to 20 mV (holding potential
at 0 mV). Data from at least two different batches of
oocytes are shown. Statistical analysis was performed on
seven or more oocytes derived from one preparation.
The error bars in the diagram were calculated from the
standard error of mean (SEM).
Immunostaining of mutant ROMK in HEK293 cells
HEK293 cells were grown in Earle’s minimal essential
medium (MEM) supplemented with 10% fetal calf serum,
penicillin/streptomycin, l-glutamine, and nonessential
amino acids on 8-well LabTeks for immunocytochemis-
try (Nalge Nunc International, Rochester, MN, USA).
Subsequently, cells were transfected with 0.5 to 0.8 g
of mutant and wild-type hROMK cDNA as described
by the manufacturer (TransFast; Promega, Madison, WI,
USA).
Chemical treatment
Cells for aminoglycoside treatment were grown as de-
scribed above. After transfection, G-418 (PAA Labora-
tories, Germany) or gentamicin (Gibco, Invitrogen Diag-
nostics, Karlsruhe, Germany) was added to the growth
medium at the indicated concentrations. After 18 to 22
hours’ incubation time, HEK293 cells were analyzed by
confocal microscopy and Western blot.
Confocal microscopy
Laser-scanning confocal microscopy was used to deter-
mine the cellular localization of pEGFP-ROMK wild-
type and mutants in HEK293 cells. The localization was
visualized with the Olympus Fluoview confocal laser-
scanning microscope (Olympus Optical BX50WI, Ham-
burg, Germany) and analyzed by cutting 7 to 11 sections
at a distance of 0.5 to 1 m using FluoView 2.1 software.
Western blot analysis
For Western blot analysis, HEK 293 cells were lysed in
Laemmli sample buffer and heated at 95C for 5 minutes.
Subsequently, proteins were separated by 12% sodium
dodecyl sulfate (SDS) gel electrophoresis and transferred
to a nitrocellulose membrane (Hybond-C Extra, Amer-
sham Life Science, Freiburg, Germany). After blocking
in 5% milk overnight, the blot was incubated with anti-
HA 1:800 (Roche Diagnostics, Mannheim, Germany)
and a horseradish peroxidase-conjugated secondary anti-
body 1:2000 (Amersham Bioscience, UK). Detection was
carried out using a chemiluminescence kit (ECL;
Amersham Biosciences, Buckinghamshire, UK) accord-
ing to the manufacturer’s instructions.
RESULTS
Mutational analysis
In addition to 13 ROMK mutations that had been pub-
lished previously [7, 11, 13], six new mutations, T71M,
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Table 1. Characterization of the new ROMK mutations
Nucleotide Homozygous/
Patient Mutation exchange heterozygous
1 T71Ma ACGATG Homozygous
2 Y79Ha TACCAC Heterozygous
insCpos353362X Heterozygous
3 F95Sa TTTTCT Heterozygous
delAAAGpos332368X Heterozygous
4 A177Ta GCCACC Homozygous
5 A306Ta GCTACT Heterozygous
6 Y314Ca TATTGT Heterozygous
R311W CGGTGG Heterozygous
a Indicates new ROMK mutations which are investigated in this study; nucleo-
tides are numbered according to their position in hROMK1
Y79H, F95S, A177T, A306T, and Y314C (for detailed
information, see Table 1) were identified in patients who
exhibited the typical clinical features of HPS/aBS. Ex-
cept for A177T, all point mutations affect amino acid
positions that are highly conserved among the inwardly
rectifying K channels family.
Mutations were discerned from polymorphisms by
demonstration of their absence in 100 control chromo-
somes and by cosegregation with the disease phenotype
within the families.
ROMK distribution in Xenopus oocytes
To study the subcellular localization of wild-type and
mutant ROMK protein, immunostaining of oocytes was
performed. Positive membrane staining was shown in
oocytes expressing ROMK wild-type (Fig. 2A), whereas
no membrane staining was observed in water-injected
oocytes (Fig. 2B).
Membrane staining was also observed for F95S,
A156V, A177T, and R311W after injection of 0.1 ng
cRNA (Fig. 2C).
In contrast, no membrane localization after injection
of 0.1 ng cRNA was detected for T71M, V72E, D74Y,
W77X, Y79X, Y79H, D108H, V122E, G167E, A198T,
L220F, A306T, Y314C, L320P, R324L, and F325C, which
were retained exclusively in the cytosolic compartment
(Fig. 2D).
Electrophysiology
The electrophysiologic properties of the ROMK muta-
tions were analyzed by heterologous expression in Xeno-
pus oocytes and two-electrode voltage clamp analysis.
As reported previously, expression of 0.1 ng wild-type
ROMK cRNA in Xenopus oocytes gave rise to weakly
inwardly rectifying potassium currents [11]. Strongly re-
duced current amplitudes were observed for all muta-
tions tested in this study after expression of 0.1 ng cRNA
(Fig. 3).
Immunostaining of ROMK mutations in HEK293 cells
To study the subcellular localization of the ROMK
mutants in a mammalian kidney cell line, transfection of
Fig. 2. Examples of oocytes injected with 0.1 ng cRNA. Correct inser-
tion in the oocyte membrane is shown in wild-type (WT)-ROMK ex-
pressing oocytes (A) and the R311W mutant (C). In contrast, negative
staining is demonstrated in water (H2O)-injected oocytes (B) and F325C
(D), indicating intracellular retention of this mutant. Arrows indicate
the plasma membrane.
mutations in HEK293 cells was performed. As expected,
membrane staining was observed for the ROMK wild-type
(Fig. 4A), whereas for the early inframe stop mutation
W77X only intracellular staining was detected (Fig. 4B).
Analogously to the expression in Xenopus oocytes,
membrane staining was shown for the F95S, A156V,
A177T, and R311W (Fig. 4C).
In contrast, no membrane staining was observed for
the following mutations: T71M, V72E, D74Y, Y79H,
D108H, V122E, G167E, A198T, A306T, L320P, R324L,
and F325C, confirming the results obtained in oocytes
(Fig. 4D).
The results of the functional analysis and immunoflu-
orescence in Xenopus oocytes and immunofluorescence
in HEK293 cells are summarized in Table 2.
Rescue of trafficking mutations (class II) by
overexpression
As mentioned before, the ROMK mutations T71M,
Y79H, A198T, L220F, A306T, and R324L were not visi-
ble in the plasma membrane after injection of 0.1 ng cDNA.
Increasing expression levels of the mutated ROMK pro-
teins, however, induced a partial restoration of mem-
brane trafficking. After injection of the tenfold excess of
cRNA (1 ng), positive membrane staining was detected
indicating forced routing to the membrane (Fig. 5). In
contrast, overexpression of the remaining mutants did
not result in correct membrane insertion.
After injection of 0.1 ng cRNA, the ROMK mutations
T71M, Y79H, A198T, L220F, A306T, and R324L showed
no or only low potassium currents. In parallel to increased
membrane localization after injection of 1 ng cRNA, we
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Fig. 3. Functional analysis of 20 ROMK mu-
tations after expression of 0.1 ng cRNA. Cur-
rent amplitudes were measured at a voltage
step of –10 mV at an ambient K concentra-
tion of 98 mmol/L, pH 7.4. Data are given as
mean  SEM.
Fig. 4. Examples of ROMK expression of each group in HEK293 cells.
A membrane negative staining pattern is demonstrated for an early
stop mutation W77X (B), and F325C (D), whereas staining in the plasma
membrane is shown in ROMK-wild-type (WT) expressing HEK293
cells (A) and A177T (C). Confocal images obtained from 5 to 11 optic
sections are shown.
observed a significant increase (P  0.05) in functional
expression: 86% 9% for T71M, 20% 4.5% for Y79H,
14%  3.5% for A198T, 29%  3% for L220F, 71% 
4.5% for A306T, and 26%  4.5% for R324L of wild-
type currents (N  7) (Fig. 6).
Overexpression of wild-type ROMK cRNA rapidly
killed oocytes within the first 24 hours; therefore, all
results obtained were referred to the wild-type currents
obtained after injection of 0.1 ng cRNA.
Rescue of preterm stop mutations (class I) after
application of aminoglycosides
To determine whether aminoglycosides could lead to a
suppression of spurious preterm stop-codons in ROMK,
HEK293 cells transfected with W77X and Y79X cDNA
were grown in the presence of gentamicin and G-418 at
the indicated concentrations. As expected, no full-length
protein could be detected in protein preparations from
control cells. However, a 73 kD band corresponding to
the full-length protein (GFP) appeared after incubation
of 0.1 to 0.2 g/mL gentamicin and 0.05 to 0.15 g/mL
G-418 (Fig. 7).
Immunofluorescence analysis of aminoglycoside-treated
cell cultures revealed a positive membrane staining in a
subset of transfected HEK293 cells. Depending on the stop-
mutation and the aminoglycoside concentration, about 5%
to 10% of transfected cells showed a positive membrane
staining with a slightly higher rate for W77X than for Y79X
as estimated by confocal microscopy. In addition, amino-
glycoside treatment significantly changed the immuno-
fluorescence pattern. The truncated proteins in absence
of aminoglycosides were solely restricted to a small area
around the nuclei probably reflecting the endoplasmic
reticulum, whereas a more diffuse distribution within the
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Table 2. Summary of the electrophysiologic and immunofluorescent results with subsequent classification into mutational classes (adopted from [16])
Membrane Membrane Membrane
staining staining Currents Currents staining Mutational
0.1 ng (oocyte) 1 ng (oocyte) 0.1 ng (oocyte) 1 ng (oocyte) (HEK293) class
WT     
W77X      I
Y79X      I
V72E      II
D74Y      II
D108H      II
V122E      II
G167E      II
Y314C      II
L320P      II
F325C      II
T71M   ()   II rescue
Y79H      II rescue
A198T      II rescue
L220F      II rescue
A306T      II rescue
R324L      II rescue
F95S      III/IV
A156V      III/IV
A177T      III/IV
R311W      III
Fig. 5. Oocytes injected with 0.1 ng (A) and 1 ng cRNA (B) are shown
with negative membrane staining after expression of 0.1 ng cRNA and
positive membrane-staining after injection of the tenfold excess of cRNA.
cell was observed after application of aminoglycosides,
possibly reflecting escape from the endoplasmic reticu-
lum and further transport to the Golgi (Fig. 8).
DISCUSSION
This study examined six new ROMK mutations and
13 of 37 ROMK mutations that have been described
before [5, 7, 10–14]. The distribution of these mutations
within the N-terminus, the channel core region, and the
C-terminus of ROMK implies different pathogenic
mechanisms, including (1) a fundamental disturbance of
the pore forming components with impaired K conduc-
tance, (2) defective regulation of ROMK, and/or (3) a
disturbed processing or trafficking to the cell surface. In
addition, also inframe stop mutations resulting in trun-
cated proteins and mutations disturbing the promoter
region have been described [5, 7, 10, 24].
Considering the electrophysiologic and immunofluo-
rescent results of expression in Xenopus oocytes and
HEK293 cells, four different groups of ROMK mutations
were distinguished.
The first group consisted of F95S, A156V, A177T, and
R311W that reached the plasma membrane both in Xeno-
pus oocytes and HEK293 cells, but showed no functional
expression under physiologic conditions. Analogous to the
CFTR-classification mentioned before, these mutations
can be assigned to class III/IV, two classes which have
been shown to be difficult to repair (class III) or only by
combining different pharmacologic agents (class IV) [16].
The pathogenic mechanism of R311W was described
previously and was shown to be associated with distur-
bances in the pH-dependent gating of ROMK [11]. Since
mutations at amino acid position 95, 156, and 177 are
located within the two transmembrane domains, a distur-
bance of the pH gating seems unlikely. The decreased
K conductance of these mutants might either result
from conformational changes of the pore forming do-
mains or a disturbed assembly, which has been shown
to require multiple interaction sites in the core region
and cytoplasmic termini of ROMK [25].
The second group consisted of V72E, D74Y, D108H,
V122E, G167E, Y314C, L320P, and F325C. Mutations
of this group showed a disturbed trafficking to the plasma
membrane and no functional expression in electrophysi-
ologic recordings. Mutations of this group could not be
rescued by overexpression of the protein.
Concerning the expression of the V72E and V122E
mutants, differing results in the electrophysiologic re-
cordings and immunofluorescence in Xenopus oocytes
have been shown by Starremans et al [14]. Differences
in the immunofluorescence might either arise from dif-
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Fig. 6. Functional analysis of 20 ROMK mu-
tations after expression of 0.1 ng () and 1 ng
() cRNA. Current amplitudes were mea-
sured at a voltage step of –10 mV at an ambient
K concentration of 98 mmol/L, pH 7.4. Data
are given as mean  SEM.
Fig. 7. Western blot analysis of ROMK Y79X after treatment with
gentamicin and G-418 after 22 hours incubation time. Ø indicates un-
transfected HEK cells.
ferent sections selected from opposite hemispheres of
the oocytes or from the use of different splice forms of
the ROMK protein that might also explain the differing
electrophysiologic results. We used ROMK1 in our study,
whereas the ROMK2 splice form, which lacks the first
19 residues compared to ROMK1, was used in the study
from Starremans et al [14]. Therefore, an additional in-
fluence of the first residues on trafficking and functional
expression of ROMK in Xenopus oocytes cannot be ruled
out. However, as already shown by Derst et al [15],
mutations that are located near the transmembrane do-
mains or the core region (amino acids 84 to 180) com-
pletely abolish functional expression, whereas mutations
in the N- and C-termini only partially reduce current
amplitudes, which is also confirmed by our results. None
of our ROMK mutations, which are located around the
core region, exhibited any functional expression, neither
after expression of 0.1 ng or 1 ng cRNA as demonstrated
in Figure 6.
In this group, an impaired trafficking to the cell surface
was shown, which might result from either defective protein
folding leading to prolonged endoplasmic reticulum–chap-
erone binding and degradation or disturbed endoplasmic
reticulum retentions signals. Endoplasmic reticulums ex-
port signals have recently been described in the C-terminal
domain of Kir2 and Kir3 channels [26–28]. C-terminal
truncation or substitution with homologous regions from
Kir channels containing no export signal strongly re-
duced or completely abolished surface expression of these
Kir subunits. Therefore, it is not surprising that several
C-terminal ROMK mutations also show trafficking de-
fects. Interestingly, transferring the ROMK C-terminal
domain (but not the C-terminus of Kir3.1, Kir3.4, Kir6.1,
and Kir6.2) to Kir2.1 channels was still capable with
plasma membrane expression, indicating that the ROMK
C-terminus may harbor endoplasmic reticulum export
signals [26].
The third group comprises T71M, Y79H, A198T,
L220F, A306T, and R324L that could be successfully
rescued by overexpression and overwhelming the cellu-
lar quality control machinery of oocytes by a tenfold
excess of cRNA. This group showed no functional ex-
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Fig. 8. Expression of ROMK W77X (A to C )
and Y79X (D to F) in HEK293 cells before and
after treatment with gentamicin (genta) and
G-418 after 18 to 22 hours incubation time.
pression after expression of 0.1 ng cRNA but a restora-
tion of K currents to 14% to 86% of wild-type currents
after expression of 1 ng cRNA.
Forced routing to the plasma membrane by overex-
pression has already been shown before for three ROMK
mutations and mutant aquaporin-2 water channels in-
volved in nephrogenic diabetes insipidus, indicating in-
tracellular retention mechanisms [14, 29]. It appears that
these point mutations can alter protein conformation in
a way that affects solely the trafficking but not the protein
function, as no fundamental disturbance of the K con-
ductance characteristics occurred. This finding could have
important implications in terms of strategies to correct
some of the ROMK mutations in HPS/aBS patients. Phar-
macologic rescue that permits plasma membrane local-
ization might be sufficient to correct proper ion channel
function, even if the perfect native conformation is not
achieved.
Concerning A198T, differering results were observed
compared to the study of Starremans et al [14] who
found approximately 85% of wild-type currents after
expression of 25 pg of A198T cRNA (which corresponds
to A179T in hROMK2) with positive membrane staining
in Xenopus oocytes. However, we did not detect mem-
brane staining or functional expression at low expression
levels. This result is in accordance with observations of
Derst et al [15], and Schulte and Fakler [30] who showed
very low or absent functional expression of A198T.
Interestingly, for ROMK-L220F, a pH-dependent gat-
ing was shown from Schulte et al [11]. This result might
combine the effects of impaired processing at low expres-
sion levels, on one hand, and a regulation defect after
overexpression, on the other hand, leading to only partial
K currents under physiologic pH conditions as observed
in our study. Similarly, combined mechanisms must be
postulated for the T71M, Y79H, A198T, A306T, and
R324L mutants that also show only partial K currents
compared to the wild-type after overexpression in oo-
cytes. Beside pH shifting effects, as already discussed for
the L220F, additional regulatory mechanisms might be
disturbed in the remaining mutations of this group such
as adenosine triphosphate (ATP)-binding or phosphory-
lation.
The structural integrity of N- and C-terminal domains
has been shown for ROMK [11] as well as for other
Kir subunits [31, 32]. Mutations in either part may have
profound structural effect on the entire cytosolic domain
of Kir channels. In addition, due to the three-dimen-
sional structure, functional important domains are often
distributed over the entire cytosolic domain (e.g., multi-
ple N- and C-terminal endoplasmic reticulum export mo-
tifs, pH sensor, or multiple interaction sites for assembly)
[11, 25, 27]. Therefore, multiple pathophysiologic mecha-
nisms resulting from a single mutation, like reduced mem-
brane expression and disturbed pH gating of ROMK,
might be explained by a severe structural disturbance in
the cytosolic domains.
The fourth group encompasses two preterm stop muta-
tions W77X and Y79X that are susceptible to suppres-
sion by aminoglycosides. As shown before, aminoglyco-
side binding is thought to induce a conformational change
at the decoding site that leads to a reduction in proof-
reading with an increase of misincorporation of near-
cognate aminoacyl-tRNAs [33]. The substitution is not
fully effective leading to restoration of only a small frac-
tion of normal levels of wild-type transcripts [34]. In
former studies, it has been shown that, depending on
the aminoglycoside, the identity of the stop-codon and
its sequence context, about 20% to 25% of wild-type-
levels are achievable [18, 35, 36]. In our study, we found
about 5% to 10% of wild-type-levels in Y79X, and about
10% to 20% in W77X, as estimated by the confocal mi-
croscopy/immunofluorescence. These results are compa-
rable to the study of Keeling and Bedwell [22], showing
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Fig. 9. Classification into five mutational classes
(adopted from [16]), according to the underly-
ing defect and assignment of the ROMK muta-
tions investigated in our study together with
ROMK mutations that had been clarified be-
fore [10, 11, 24] into these classes.
that the tetranucleotide UGA/C (W77X) is more readily
suppressed than UAG/A (Y79X) by gentamicin in a
mammalian translation system. However, only a small frac-
tion of suppressed ROMK preterm stop mutations dis-
played a positive membrane staining in our study (see
Fig. 8), which has also been shown before by others [37].
In their study, Bedwell et al [37] found that, after incuba-
tion of CFTR-W1282X with G-418, full-length CFTR
was expressed. However, they were unable to detect the
repaired protein at the apical membrane without further
cyclic adenosine monophosphate (cAMP) stimulation
indicating that G-418 restored first the expression of full-
length CFTR and that the resulting functional protein
was trafficked to the apical membrane after cAMP stimu-
lation in a second step. As the ribosome is introducing
not only the original tRNA but also missense mutations,
an impaired trafficking to the cell membrane in a subset
of suppressed proteins is presumable. However, even
partial restoration of ROMK function might be sufficient
to effectively alleviate the disease phenotype.
In contrast to premature translation termination co-
dons introduced by mutations, naturally occurring termi-
nation codons are thought to lie within a context that
promotes efficient translation termination [23], as recog-
nition of translation termination signals is not only lim-
ited to the trinucleotide codons UGA, UAG, UAA. It
is, instead, recognized by an extended tetranucleotide
termination signal composed of the stop-codon and the
first nucleotide that follows (e.g., purine nucleotides fol-
lowing the stop promote translation termination more
efficiently than stop-codons followed by pyrimidines)
[22, 38]. Therefore, naturally occurring stop mutations
might be protected more effectively by a special environ-
ment than stop-codons introduced by mutations. This is
confirmed by former studies showing no significant side
effects after treatment with G-418 in cell culture experi-
ments [18] or gentamicin in a clinical study [23].
Analogous to the classification of CFTR mutations [16],
we assigned the ROMK mutations investigated in our
study into the five mutational classes (see also Table 2).
Together with those ROMK mutations that have already
been functionally analyzed before, more than 50% of
the ROMK mutations show a trafficking defect (Fig. 9).
Thus, defective ROMK processing seems to be the
predominant pathogenic mechanism leading to HPS/
aBS, which is most favorable in terms of new pharmaco-
logic approaches that aim at the rescue of the mistraf-
ficked protein. Thus, in ROMK-mutations, butyrates or
specific ROMK agonists/antagonists might also overcome
the trafficking defects of class II mutations, whereas cer-
tain aminoglycosides might be useful for ROMK stop
mutations of class I.
Loss-of-function mutations have also been described
in other members of the Kir family, such as the Kir6.1
associated with familial persistent hyperinsulinemic hy-
poglycaemia of infancy [39] and the Kir2.1 leading to
Andersen syndrome, which is characterized by periodic
paralysis, cardiac arrhythmias, and dysmorphic features.
Although no detailed functional characterization is avail-
able for the Kir2.1 mutations, it is tempting to speculate
that several mutations in the N- and C-terminal region
might also affect membrane trafficking. Therefore, iden-
tification of different pathophysiologic mechanisms in
ROMK and pharmacologic restoration of trafficking mu-
tations or inframe stop mutations might have significant
implication for treatment of other defective members of
the Kir family [40].
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